EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Joseph F Merola, Philip Mease iD, Alan Kivitz, Naveed Sattar, Laura C Coates iD, Daniel Aletaha, Cynthia E Kartman, Peter Fischer, Luna Sun, Píndaro Martínez-Osuna, Andris Kronbergs, Purvi Prajapati und 3 weitere

Arthritis & Rheumatology · 2026-10 · 78 (10) · 2089-2101

DOI: 10.1002/art.70134 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Arthritis & Rheumatology, online erschienen am 28.03.2026. Verfasst von Joseph F Merola und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Department of Medicine, Division of Rheumatology, University of Texas Southwestern Medical Center and O'Donnell School …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Psoriatic, Obesity. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.

Methods

TOGETHER‐PsA ( ClinicalTrials.gov identifier: NCT06588296) is a phase 3b, randomized, 52‐week trial in adults with active PsA and overweight (body mass index [BMI] ≥27 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, PsoriaticObesityOverweightTirzepatideAdultFemaleHumansMaleMiddle AgedDrug Therapy, CombinationTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedAntirheumatic AgentsixekizumabTirzepatide

Autor:innen und Institutionen

  • Department of Dermatology and Department of Medicine, Division of Rheumatology, University of Texas Southwestern Medical Center and O'Donnell School of Public Health, Dallas.
  • Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle.
  • Altoona Center for Clinical Research, Duncansville, Pennsylvania.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
  • Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Philip Mease, Laura C Coates

Förderung

  • Eli Lilly and Company

Zitieren

APA

Merola, J. F., Mease, P., Kivitz, A., Sattar, N., Coates, L. C., Aletaha, D., Kartman, C. E., Fischer, P., Sun, L., Martínez-Osuna, P., Kronbergs, A., Prajapati, P., Cardoso, A., Genovese, M. C., & Ogdie, A. (2026). Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis & Rheumatology, 78(10), 2089-2101. https://doi.org/10.1002/art.70134

Vancouver

Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, et al. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis & Rheumatology. 2026;78(10):2089-2101. doi:10.1002/art.70134

BibTeX
@article{Merola2026,
  author = {Merola, Joseph F and Mease, Philip and Kivitz, Alan and Sattar, Naveed and Coates, Laura C and Aletaha, Daniel and Kartman, Cynthia E and Fischer, Peter and Sun, Luna and Martínez-Osuna, Píndaro and Kronbergs, Andris and Prajapati, Purvi and Cardoso, Anabela and Genovese, Mark C and Ogdie, Alexis},
  title = {Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  volume = {78},
  number = {10},
  pages = {2089--2101},
  doi = {10.1002/art.70134}
}
Kostenlos starten →